We describe a 73-year-old 
Introduction

Systemic sclerosis (SSc) is a systemic disorder characterized by inflammation, fibrosis, and vascular obliteration of the skin and visceral organs. SSc patients occasionally develop clinical or serological feature of other connective tissue diseases, such as polymyositis (PM), dermatomyositis, and systemic lupus erythematosus. We describe a 73-year-old woman with SSc-PM overlap syndrome, primarily SSc followed by PM. SSc-PM overlap syndrome is a clinical entity with the clinical features of both SSc and PM. The patient was already suffering SSc with interstitial pneumonia (IP), and the IP had been stable. A fresh lesion developed in her lungs 8 years after the diagnosis of SSc; this is unusual for SSc-IP. Further examination revealed that the diagnostic criteria for PM were satisfied. A fresh lesion seemed to be due to the appearance of PM. This is a valuable case, in which it was observed that the pulmonary lesion due to an existing connective tissue disease was accompanied by a new pulmonary lesion due to a new overlapping condition, and it is therefore believed that reporting this case is worthwhile.
Case Report
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5,120). Anti-Jo-1 and anti-U3 RNP antibodies were positive (anti-Jo-1 by ELISA and immunoprecipitation, anti-U3 RNP antibody by immunoprecipitation), although other autoantibodies such as anti-U1/U2, anti-Sm, anti-Scl 70, anti-SS-A, and anti SS-B, were not detected. KL-6 and surfactant protein-D (SP-D) were elevated to 1,170 IU/L and 176 ng/ ml, respectively, although CPK and aldolase levels were within normal ranges. Electrocardiography (ECG) and echocardiography showed no abnormalities including right ventricular overload. A chest roentgenogram showed reticular shadows in the lower lung fields
 (Fig. 1) Ch e s t r o e n t g e n o g r a ms o b t a i n e d o v e r t h e c l i n i c a l c o u r s e . Re t i c u l a r s h a d o ws a r 
Discussion
Systemic sclerosis is an autoimmune disease characterized by a wide spectrum of clinical, pathologic, and serologic abnormalities. Circulating antibodies against a variety of nuclear and nucleolar antigens are detected in more than 95% of patients (2). SSc patients occasionally develop clinical or serological features of other connective tissue diseases, such as PM, dermatomyositis, and systemic lupus erythematosus, resulting in an overlap syndrome. The presence of anti-Ku antibody (3), anti-PM-Scl antibody (4), or anti-U1/U2 RNP antibody has been reported in patients with an SSc overlap syndrome. Anti-Ku antibody is detected in about 50% of patients in Japan with SSc-PM overlap syndrome. Anti-PM-Scl antibody is detected specifically in North American patients with SSc-PM overlap syndrome; this antibody is seldom seen in such patients in Japan, and only 10% of Caucasians with SSc-PM overlap syndrome show detectable levels of anti-Ku antibody (5). The reason for the differences in the presence of these antibodies is not clear; genetic backgrounds and environmental factors may play a role. We did not find any of these antibodies in the present patient. We did find autoantibody to U3 RNP (fibrillarin). Fibrillarin is an RNP particle that contains U3-RNA and is located in the fibrillar regions of nucleoli. The protein of the U3 RNP particle that contains the anti-genetic determinants is a 34-kd nucleolar protein. Anti-U3 RNP antibody is found in approximately 6% of SSc patients, and its presence in serum is highly specific to SSc (6, 7). Although Kuwana et al reported that anti-U3 RNP antibody is frequently detected in black patients with overlap syndrome (8), this antibody is
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Loss of pulmonary function in patients with SSc is significantly greater during the first 2 years than later in the course of the disease (9). Colp concluded that lung abnormalities associated with SSc occur early and thereafter do not progress significantly (10). Therefore, it is not natural that SSc-IP would exacerbate 8 years after the initial diagnosis of SSc. In addition, a remarked increase in the number of lymphocytes in BAL fluid is not common in cases of
